source
- Q&A: Novo research chief Petersen says streamlined R&D speeds discoveryJust as Maziar Mike Doustdar took the helm at Novo Nordisk in the summer of 2025, the company said it would reorganize its R&D activities, merging the teams that focused on early ...Endpoints · 2mo ago↗ source
- Wave aims for monthly dosing with RNA editing treatment for AATDWave Life Sciences reported an updated cut of data from its early-stage study of an RNA editing treatment for alpha-1 antitrypsin deficiency, suggesting it can dose its genetic therapy monthly. Peo…Endpoints · 2mo ago↗ source
- A migraine drugmaker heads to the public markets through reverse mergerMentari Therapeutics, a spinout from the prolific hub-and-spoke biotech Paragon, is developing two medications it hopes can treat migraines that aren’t well controlled by existing drugs.